細(xì)胞轉(zhuǎn)染注意事項,你都get了嗎？(下)
細(xì)胞轉(zhuǎn)染實驗從開始設(shè)計到最終的效果檢測，可以由6個過程組成：核酸準(zhǔn)備、試劑選擇、細(xì)胞鋪板、轉(zhuǎn)染操作、細(xì)胞培養(yǎng)、效果檢測。每一步都會影響最終的結(jié)果，均存在不同的注意事項。上個月小翌分享了前3個過程的注意事項：
細(xì)胞轉(zhuǎn)染注意事項，你都get了嗎？（上）
本期分享后面3個過程的注意事項：
轉(zhuǎn)染操作
1.條件摸索與優(yōu)化：
2.無血清配置復(fù)合物：
3.孵育時間：
4.抗生素影響：
1.優(yōu)良的培養(yǎng)試劑：
2.是否換液：
1.檢測方法的選擇：
2.檢測時間的選擇：
3.穩(wěn)轉(zhuǎn)篩選：
[1] Liu R, Yang J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. (IF:55)華東理工大學(xué)生物工程學(xué)院楊弋團隊
[2] Zhou J, Chen P, et al. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5.(IF:11.454)武漢大學(xué)生命科學(xué)學(xué)院殷雷團隊
[3] Chen S, Cao X, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Jan 24.(IF:16.808)中國科學(xué)院北京生命科學(xué)研究院趙方慶團隊
[4] Gu C, Wang Y, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團隊
[5] Zhang Y, Yu X, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022 Feb.(11.492)南京中醫(yī)藥大學(xué)楊燁顧春艷團隊
[6] Qin J, Cai Y, et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat Commun. 2022 Jan 13.(14.9)四川大學(xué)生物治療國家重點實驗室邵振華團隊
[7] Tang X, Deng Z, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團隊
[8] Xie F, Su P, et al. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. Adv Mater. 2021 Oct 19. (IF:30.849)蘇州大學(xué)生物醫(yī)學(xué)研究院周芳芳團隊和浙江大學(xué)生命科學(xué)研究院張龍團隊
[9] Liang Y, Lu Q, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7.(IF:16.9)復(fù)旦大學(xué)生物醫(yī)學(xué)研究院于文強團隊
[10] Fan Y, Wang J, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb 2.(IF:27.403)南京醫(yī)科大學(xué)附屬逸夫醫(yī)院蘇東明團隊
[11] Dai L, Dai Y, et al. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021 Jul 1.(IF:17.97)浙江大學(xué)生命科學(xué)研究院黃俊團隊和中科院生物物理所周政團隊
[12] Zhang K, Wang A, et al. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron. 2021 Jun 16.(IF:17.17)中國科學(xué)院生物與化學(xué)交叉研究中心王文元團隊
[13] Li T, Chen X, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021 Jan 27.(IF:14.92)華東理工大學(xué)生物工程學(xué)院楊弋團隊
[14] Pan Y, He X, et al. Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. Cell Rep. 2021 Jul 20.(IF:9.420)浙江大學(xué)腦科學(xué)與腦醫(yī)學(xué)學(xué)院馬歡團隊
[15] Liu H, Xing R, et al. G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production. Cell Death Dis. 2021 Jun 12.(IF:8.463)廈門大學(xué)生命科學(xué)學(xué)院陳穎團隊
[16] Yan F, Huang C, et al. Threonine ADP-Ribosylation of Ubiquitin by a Bacterial Effector Family Blocks Host Ubiquitination. Mol Cell. 2020 May 21.(IF:17.97)浙江大學(xué)生命科學(xué)研究院朱永群團隊
[17] Luo Q, Wu X, et al. TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Rep. 2020 Jan 7.(IF:9.42)中國醫(yī)學(xué)科學(xué)院分子腫瘤學(xué)國家重點實驗室劉芝華團隊
[18] Sun X, Peng X, et al. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020 Jun 12.(IF:14.911)中國科學(xué)院水生生物研究所孫玉華團隊
[19] Yang X, Wang H, et al. Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation. Protein Cell. 2020 Dec.(IF:14.872)浙江大學(xué)醫(yī)學(xué)院/轉(zhuǎn)化醫(yī)學(xué)研究院閔軍霞團隊
[20] Zou Y, Wang A, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018 Oct.(IF:13.490)華東理工大學(xué)生物工程學(xué)院楊弋、趙玉政團隊
[21] Zhang K, Zhao X, et al. Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl Mater Interfaces. 2018 Sep 12.(IF:8.09)南開大學(xué)醫(yī)學(xué)院李宗金團隊
[22] Hao H, Hu S, et al. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017 Mar 28.(IF:29.69)中國醫(yī)學(xué)科學(xué)院/北京協(xié)和醫(yī)學(xué)院阜外醫(yī)院王淼團隊
|
應(yīng)用場景 |
名稱 |
貨號 |
規(guī)格 |
|
細(xì)胞類型：貼壁/懸浮 核酸類型：DNA、siRNA |
40802ES02 |
0.5 mL |
|
|
40802ES03 |
1.0 mL |
||
|
40802ES08 |
5×1 mL |
||
|
細(xì)胞類型：貼壁/懸浮 |
40803ES70 |
200 T |
|
|
用途：病毒感染、DNA轉(zhuǎn)染 |
40804ES76 |
500 μL |
|
|
40804ES86 |
5×500 μL |
||
|
細(xì)胞類型：懸浮 |
40805ES02 |
0.5 mL |
|
|
40805ES03 |
1.0 mL |
||
|
40805ES08 |
5×1 mL |
||
|
細(xì)胞類型：貼壁/懸浮 |
40806ES01 |
0.1 mL |
|
|
40806ES02 |
0.5 mL |
||
|
40806ES03 |
1.0 mL |
||
|
細(xì)胞類型：貼壁/懸浮 |
40808ES02 |
0.5 mL |
|
|
40808ES03 |
1 mL |
||
|
40808ES08 |
5×1 mL |
||
|
細(xì)胞類型：貼壁/懸浮 |
40809ES01 |
0.1 mL |
|
|
40809ES03 |
1 mL |
||
|
細(xì)胞類型：貼壁/懸浮 |
40815ES03 |
1 g |
|
|
40815ES08 |
5×1 g |
||
|
細(xì)胞類型：貼壁/懸浮 |
40816ES02 |
100 mg |
|
|
40816ES03 |
1 g |
||
|
細(xì)胞類型：293 |
40820ES04 |
1.5 mL |
|
|
40820ES10 |
10 mL |
||
|
40820ES60 |
100 mL |
||
|
細(xì)胞類型：293 核酸類型：DNA 用途：AAV/LV載體大規(guī)模生產(chǎn) |
40821ES10 |
10 mL |
|
|
40821ES60 |
100 mL |
||
|
40821ES80 |
1 L |
